twoXAR Pharmaceuticals has built a development portfolio targeting 18+ different diseases. twoXAR’s unique approach to drug discovery combines steps from the traditional multi-step approach to R&D that severely limits the pace of drug discovery. This novel method – coupled with the company’s proprietary AI-driven platform – enables twoXAR to select a disease and initiate in vivo testing in months, instead of years.
N/A
1 to 25
Series A
$14.3M
Growth
2014
Pharmaceuticals
Managed Health Care
Healthcare
Health Care Facilities & Hospitals
N/A
N/A
Yes
Active
Machine Learning
Natural Language Processing
N/A
Software
